CN112831564B - 一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 - Google Patents
一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 Download PDFInfo
- Publication number
- CN112831564B CN112831564B CN202110175282.9A CN202110175282A CN112831564B CN 112831564 B CN112831564 B CN 112831564B CN 202110175282 A CN202110175282 A CN 202110175282A CN 112831564 B CN112831564 B CN 112831564B
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- seq
- genetic variation
- auxiliary diagnosis
- chr13
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 82
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 82
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 82
- 230000007614 genetic variation Effects 0.000 title claims abstract description 39
- 238000003745 diagnosis Methods 0.000 title claims abstract description 32
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 28
- 101150008921 Brca2 gene Proteins 0.000 description 23
- 108700010154 BRCA2 Genes Proteins 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 16
- 238000012216 screening Methods 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000009007 Diagnostic Kit Methods 0.000 description 6
- 206010018910 Haemolysis Diseases 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 238000007671 third-generation sequencing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000022602 disease susceptibility Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110175282.9A CN112831564B (zh) | 2021-02-09 | 2021-02-09 | 一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110175282.9A CN112831564B (zh) | 2021-02-09 | 2021-02-09 | 一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112831564A CN112831564A (zh) | 2021-05-25 |
CN112831564B true CN112831564B (zh) | 2023-01-03 |
Family
ID=75933083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110175282.9A Active CN112831564B (zh) | 2021-02-09 | 2021-02-09 | 一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112831564B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624453D0 (en) * | 1995-11-23 | 1997-01-15 | Cancer Res Campaign Tech | Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof |
CN104962613A (zh) * | 2015-06-02 | 2015-10-07 | 南京医科大学 | 一种用于乳腺癌辅助诊断的突变基因及其应用 |
EP3447154A1 (en) * | 2017-08-23 | 2019-02-27 | Instytut Genetyki Sadowej Jolanta Powierska - Czarny | Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics |
-
2021
- 2021-02-09 CN CN202110175282.9A patent/CN112831564B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624453D0 (en) * | 1995-11-23 | 1997-01-15 | Cancer Res Campaign Tech | Materials and methods relating to the identification and sequencing of the brca2 cancer susceptibility gene and uses thereof |
CN104962613A (zh) * | 2015-06-02 | 2015-10-07 | 南京医科大学 | 一种用于乳腺癌辅助诊断的突变基因及其应用 |
EP3447154A1 (en) * | 2017-08-23 | 2019-02-27 | Instytut Genetyki Sadowej Jolanta Powierska - Czarny | Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics |
Non-Patent Citations (2)
Title |
---|
Analyses of rare predisposing variants of lung cancer in 6,004 whole genomes in Chinese;Cheng Wang等;《Cancer Cell》;20221010;第40卷;第1223-1239页 * |
中国汉族家族性及早发性乳腺癌患者BRCA2启动子突变情况的研究;陈莹等;《中国癌症杂志》;20090915(第09期);第82-84页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112831564A (zh) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107254531B (zh) | 早发性结直肠癌辅助诊断的遗传生物标志物及其应用 | |
CN106399304B (zh) | 一种与乳腺癌相关的snp标记 | |
CN115029431A (zh) | 一种2型糖尿病基因检测试剂盒以及2型糖尿病遗传风险评估系统 | |
CN104988141A (zh) | BRCA2基因g.32912799T>C突变及其在乳腺癌辅助诊断中的应用 | |
CN109457031B (zh) | BRCA2基因g.32338309A>G突变体及其在乳腺癌辅助诊断中的应用 | |
CN107557468B (zh) | 一种与原发性肺癌辅助诊断相关的癌-睾丸基因遗传标志物及其应用 | |
CN112831564B (zh) | 一种与原发性肺癌辅助诊断相关的遗传变异区域的基因组合及其应用 | |
CN109880903B (zh) | 一种用于非小细胞肺癌辅助诊断的snp标志物及其应用 | |
CN108504660A (zh) | Adcy10基因突变体及其应用 | |
CN112695081B (zh) | 原发性胆汁性胆管炎新的易感基因及其应用 | |
CN104962612B (zh) | BRCA1基因g.41256139delT移码突变及其在制备乳腺癌辅助诊断试剂盒中的应用 | |
CN104962613B (zh) | 一种用于乳腺癌辅助诊断的突变基因及其应用 | |
CN108342488B (zh) | 一种用于检测胃癌的试剂盒 | |
CN108441560B (zh) | 一种位于cep128基因的与放疗引起的放射性脑损伤相关的snp标志物及其应用 | |
CN106868128B (zh) | 一组辅助诊断乳腺癌的生物标记物及其应用 | |
CN106636351B (zh) | 一种与乳腺癌相关的snp标记及其应用 | |
CN115820654A (zh) | Loxhd1基因突变体及其应用 | |
CN104946751A (zh) | BRCA1基因g.41244291delT突变及其在乳腺癌辅助诊断中的应用 | |
CN110205322B (zh) | 一种乳腺癌致病基因sec63的突变snp位点及其应用 | |
CN111808955B (zh) | 一种与肺癌相关的外周血regQTLs生物标志物及其应用 | |
CN106834476A (zh) | 一种乳腺癌检测试剂盒 | |
CN114427002B (zh) | 基于22个snp易感位点评估1型糖尿病患病风险的试剂盒 | |
CN106520957B (zh) | Dhrs7易感snp位点检测试剂及其制备的试剂盒 | |
CN113913521B (zh) | 一种基因分型检测试剂盒及其应用 | |
CN111560430B (zh) | 检测rs1766位点多态性的试剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210525 Assignee: Suzhou Nanyi University Innovation Center Assignor: NANJING MEDICAL University Contract record no.: X2023980033925 Denomination of invention: Gene combination of a genetic variation region associated with auxiliary diagnosis of primary lung cancer and its application Granted publication date: 20230103 License type: Common License Record date: 20230322 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Suzhou Nanyi University Innovation Center Assignor: NANJING MEDICAL University Contract record no.: X2023980033925 Date of cancellation: 20230810 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210525 Assignee: Suzhou Dean Medical Laboratory Co.,Ltd. Assignor: NANJING MEDICAL University Contract record no.: X2023980040501 Denomination of invention: Gene combination and application of a genetic variation region related to auxiliary diagnosis of primary lung cancer Granted publication date: 20230103 License type: Exclusive License Record date: 20230825 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Suzhou Dean Medical Laboratory Co.,Ltd. Assignor: NANJING MEDICAL University Contract record no.: X2023980040501 Date of cancellation: 20240312 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210525 Assignee: NANJING DIAN MEDICAL LABORATORY CO.,LTD. Assignor: NANJING MEDICAL University Contract record no.: X2024980005344 Denomination of invention: Gene combination and application of a genetic variation region associated with auxiliary diagnosis of primary lung cancer Granted publication date: 20230103 License type: Exclusive License Record date: 20240509 |